Baseline characteristics for presence or absence of CSVD
| Variables | CSVD (Wardlaw) | P value | CSVD (Rothwell) | P value | ||
| Presence of CSVD (n=934) | Absence of CSVD (n=2127) | Presence of CSVD (n=1271) | Absence of CSVD (n=1790) | |||
| Demographic data | ||||||
| Age, mean±SD | 64.6±6.7 | 59.7±6.1 | <0.001 | 63.7±6.7 | 59.4±6.1 | <0.001 |
| Male, n (%) | 485 (51.9) | 939 (44.2) | <0.001 | 610 (48.0) | 814 (45.5) | 0.17 |
| Current smoking, n (%) | 185 (19.8) | 442 (20.8) | 0.54 | 244 (19.2) | 383 (21.4) | 0.14 |
| BMI (kg/m2), median (IQR) | 23.7 (21.6–25.8) | 23.5 (21.7–25.6) | 0.43 | 23.7 (21.6–25.8) | 23.5 (21.7–25.6) | 0.31 |
| Laboratory data, median (IQR) | ||||||
| FPG (mmol/L) | 5.7 (5.3–6.3) | 5.5 (5.2–6.0) | <0.001 | 5.64 (5.3–6.3) | 5.5 (5.2–6.0) | <0.001 |
| Total cholesterol (mmol/L) | 5.2 (4.5–5.9) | 5.2 (4.6–5.9) | 0.31 | 5.2 (4.6–5.9) | 5.3 (4.6–5.9) | 0.18 |
| HDL (mmol/L) | 1.3 (1.1–1.5) | 1.3 (1.1–1.6) | 0.16 | 1.3 (1.1–1.6) | 1.3 (1.1–1.6) | 0.29 |
| eGFR (mL/min/1.73 m2) | 100.9 (92.0–107.9) | 105.9 (98.5–111.1) | <0.001 | 101.8 (93.4–108.2) | 106.2 (98.9–111.3) | <0.001 |
| Medical history, n (%) | ||||||
| Hypertension | 547 (58.6) | 770 (36.2) | <0.001 | 709 (55.8) | 608 (34.0) | <0.001 |
| Diabetes | 251 (26.9) | 410 (19.3) | <0.001 | 331 (26.0) | 330 (18.4) | <0.001 |
| Dyslipidaemia | 201 (21.5) | 413 (19.4) | 0.18 | 249 (19.6) | 365 (20.4) | 0.59 |
| Concomitant medication, n (%) | ||||||
| Antihypertensive | 371 (39.7) | 449 (21.1) | <0.001 | 474 (37.3) | 346 (19.3) | <0.001 |
| Lipid-lowing | 51 (5.5) | 69 (3.2) | 0.004 | 65 (5.1) | 55 (3.1) | 0.004 |
| Antidiabetic | 117 (12.5) | 156 (7.3) | <0.001 | 152 (12.0) | 121 (6.8) | <0.001 |
| Antiplatelet | 40 (4.3) | 40 (1.9) | <0.001 | 51 (4.0) | 29 (1.6) | <0.001 |
| Anticoagulants | 3 (0.32) | 1 (0.05) | 0.16 | 3 (0.24) | 1 (0.06) | 0.39 |
BMI, body mass index; CSVD, cerebral small vessel disease; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HDL, high density lipoprotein.